Last reviewed · How we verify
NCT05280769
Effects of an Oral Nicotine Product in Smokeless Tobacco Users
NA trial testing oral nicotine pouch - 2 mg in Tobacco Use in 31 participants. Completed in 28 November 2023.
28 November 2023
Quick facts
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 31 |
| Start date | 23 August 2022 |
| Primary completion | 28 November 2023 |
| Estimated completion | 28 November 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- oral nicotine pouch - 2 mg
- oral nicotine pouch - 4 mg
- oral nicotine pouch - 8 mg
- Smokeless tobacco — full drug profile →
Conditions studied
- Tobacco Use — all drugs for Tobacco Use →
Sponsor
Virginia Commonwealth University
Who can join
Adults 18 to 55, any sex, with Tobacco Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to find out how three different nicotine pouches and participant's own brand of smokeless tobacco affect blood nicotine levels and how participants feel.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Physiological and subjective effects of an oral nicotine pouch in people who use smokeless tobacco.
Eversole A, Imran R, Gaitan N, Cobb CO, et al · · 2025 · PMID 40839513 · DOI 10.1037/pha0000798
Verify or expand the search:
- PubMed search for NCT05280769
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tobacco Use
Currently open trials in the same condition.
- NCT07162935 — Cigar Legislation and Regulation in Tobacco for the Young (Project CLARITY) · NA · recruiting
- NCT07132814 — Abuse Liability for Five Modern Oral Nicotine Products · NA · recruiting
- NCT07148232 — Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness · Phase 4 · recruiting
- NCT06983678 — Neural Correlates and Behavioral Impact of Withdrawal-induced Hyperalgesia Among People Who Smoke With and Without Chron · NA · recruiting
- NCT06922617 — STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking · NA · recruiting
Other Virginia Commonwealth University trials
Trials by the same sponsor.
- NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
- NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
- NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05280769 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
- Last refreshed: 2 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05280769.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing